Eltrombopag: A Review of Its Use in the Treatment of Thrombocytopenia in Patients with Chronic Hepatitis C
- 481 Downloads
Eltrombopag (Revolade®; Promacta®) is an orally bioavailable, small-molecule, thrombopoietin receptor agonist that selectively binds to thrombopoietin receptors on megakaryocyte precursors and megakaryocytes leading to increased platelet production. It is approved in a number of countries for the treatment of thrombocytopenia, including adult patients with chronic hepatitis C virus (HCV) infection to allow for the initiation and maintenance of peginterferon-based therapy, which is the focus of this review. In two, well-designed, randomized controlled trials in adults with chronic HCV infection and thrombocytopenia (ENABLE-1 and ENABLE-2), eltrombopag increased platelet counts to sufficient levels to allow for the initiation of peginterferon-based antiviral therapy in 95 % of patients whose baseline platelet counts would have made them ineligible or marginal candidates for peginterferon therapy. Moreover, a significantly higher proportion of eltrombopag recipients than placebo recipients achieved a sustained virological response (primary endpoint) 24 weeks after the completion of antiviral therapy. Of note, the additional benefit over placebo was relatively small (<10 %). Compared with placebo, eltrombopag was associated with fewer patients discontinuing antiviral therapy early and a numerically greater proportion of patients not requiring antiviral dose reduction. Oral eltrombopag had an acceptable tolerability profile; however, there is an increased risk of adverse events, including potentially fatal hepatic decompensation and thromboembolic events. Eltrombopag provides a new treatment option for thrombocytopenia in patients with chronic HCV infection to allow for optimal antiviral therapy.
KeywordsSustained Virologic Response Sustained Virologic Response Rate Eltrombopag Hepatic Decompensation Breast Cancer Resistance Protein Substrate
The preparation of this review was not supported by any external funding. Celeste B. Burness is a salaried employee of Adis/Springer. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made by the author on the basis of scientific and editorial merit.
- 2.World Health Organization. Guideline for the screening, care and treatment of persons with hepatitis infection. 2014. http://apps.who.int/iris/bitstream/10665/111747/1/9789241548755_eng.pdf?ua=1. Accessed 12 Sept 2014.
- 4.American Association for the Study of Liver Diseases and the Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C. 2014. http://www.hcvguidelines.org/. Accessed 10 Aug 2014.
- 6.Genentech Inc. PEGASYS (peginterferon alfa-2a): US prescribing information. 2013. http://www.gene.com/download/pdf/pegasys_prescribing.pdf. Accessed 15 Sept 2014.
- 7.Merck and CO. PEGINTRON® (peginterferon alfa-2b) injection, for subcutaneous use: US prescribing information. 2013. http://www.merck.com/product/usa/pi_circulars/p/pegintron/pegintron_pi.pdf. Accessed 15 Sept 2014.
- 10.Danish FA, Koul SS, Subhani FR, et al. Considerations in the management of hepatitis C virus-related thrombocytopenia with eltrombopag. Saudi J. 2010;16(1):51–6.Google Scholar
- 12.GlaxoSmithKline. Revolade 25 mg film-coated tablets: summary of product characteristics. 2014. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001110/WC500089964.pdf. Accessed 15 Sept 2014.
- 13.GlaxoSmithKline. PROMACTA® (eltrombopag) tablets: US prescribing information. 2014. http://www.gsksource.com/gskprm/htdocs/documents/PROMACTA-PI-MG-COMBINED.PDF. Accessed 15 Sept 2014.
- 19.European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP) group of an extension of marketing authorisation and variations assessment report for Revolade (eltrombopag): procedure no. EMEA/H/C/001110/X/0012G. 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/001110/WC500152310.pdf. Accessed 15 Sept 2014.
- 31.Jenkins J, Williams D, Deng Y, et al. Eltrombopag, an oral thrombopoietin receptor agonist, has no impact on the pharmacokinetic profile of probe drugs for cytochrome P450 isoenzymes CYP3A4, CYP1A2, CYP2C9 and CYP2C19 in healthy men: a cocktail analysis. Eur J Clin Pharmacol. 2010;66(1):67–76.CrossRefGoogle Scholar
- 33.Afdhal N, Giannini EG, Sigal S, et al. Improved SVR in a unique cohort of non-cirrhotic thrombocytopenic patients with hepatitis C virus (HCV) treated in the global multicenter ENABLE 1 and 2 trials [abstract 1725]. Hepatology. 2012;56(Suppl 4):995A.Google Scholar
- 34.Berg T, Riordan S, Karamanolis D, et al. ENABLE-ALL: safety and efficacy of eltrombopag in thrombocytopenic hepatitis C virus-infected patients with cirrhosis who withdrew from the ENABLE-1&2 studies [abstract no. 140]. In: 23rd annual conference of APASL, Brisbane; 2014.Google Scholar
- 35.Chen PJ, Han KH, Dusheiko GM, et al. Eltrombopag as a supportive agent to enable antiviral therapy in east asian patients with thrombocytopenia and hepatitis C virus [abstract no. 1988 plus poster]. Hepatol Int. 2013;7(Suppl 1):S417–S8.Google Scholar
- 36.Merck. Rebetol® (ribavirin): US prescribing information. 2013. https://www.merck.com/product/usa/pi_circulars/r/rebetol/rebetol_pi.pdf. Accessed 15 Sept 2014.
- 37.Afdhal N, Giannini EG, Sigal S, et al. Albumin and MELD score predict decompensation in patients with HCV cirrhosis and thrombocytopenia on interferon therapy: analysis from the ENABLE studies [abstract 1138 plus poster]. Hepatology. 2012;56(Suppl 4):738A–9A.Google Scholar